The VALOR trial and its open label extension demonstrated the efficacy of the antisense oligonucleotide (ASO), tofersen, in familial amyotrophic lateral sclerosis (ALS) caused by variants in the SOD1 gene (SOD1‐ALS). Here, SOD1 is linked to familial amyotrophic lateral sclerosis.